Kim E.S.Melosky B.Park K.Yamamoto N.CHIH-HSIN YANG2022-08-102022-08-1020211479-6694https://www.scopus.com/inward/record.uri?eid=2-s2.0-85106932597&doi=10.2217%2ffon-2021-0195&partnerID=40&md5=b36f999ca632bb5d04b1be26486a0d9dhttps://scholars.lib.ntu.edu.tw/handle/123456789/616503Few data are available that have compared outcomes with different EGFR tyrosine kinase inhibitors (TKIs) specifically in Asian patients with EGFR mutation-positive non-small-cell lung cancer. In this narrative review, we have collated available data from prospective studies that have assessed first-, second- and third-generation EGFR TKIs in Asian populations, including subanalyses in individual countries (China and Japan). These data indicate that outcomes with first- and second-generation TKIs are broadly similar in Asian and non-Asian populations. However, while the third-generation EGFR TKI, osimertinib, confers significant overall survival benefit over erlotinib/gefitinib in non-Asians, this is not apparent in Asians, particularly in countries like Japan with well-resourced healthcare. Head-to-head comparisons of second- and third-generation EGFR TKIs, with OS as a primary end point, should be considered in Asia.[SDGs]SDG3[SDGs]SDG17review10.2217/fon-2021-0195338558652-s2.0-85106932597